Rohan Katipally
Papers
2
Total Citations
8
H-Index
1
About
Rohan Katipally is a clinical researcher whose work is reshaping the treatment landscape for human papillomavirus-associated oropharyngeal cancer (HPV+ OPSCC). His primary focus lies in precision oncology and therapeutic de-escalation, aiming to reduce the severe, life-altering toxicities of standard chemoradiation without compromising survival. Katipally’s key contribution is the development and validation of circulating tumor HPV DNA (ctHPV-DNA) as a dynamic, noninvasive biomarker. His landmark 2025 study, with 7 citations, demonstrated that early ctHPV-DNA kinetics during neoadjuvant chemotherapy can identify patients who are excellent candidates for response-adapted de-escalation, offering a path to less toxic, personalized treatment. He further advanced this paradigm through a pooled analysis of functional and survival outcomes, showing that such de-escalation strategies preserve swallowing function and quality of life while maintaining excellent oncologic control. By bridging molecular monitoring with clinical decision-making, Katipally is pioneering a shift from one-size-fits-all therapy to biomarker-driven, toxicity-sparing care, directly improving the lives of patients with HPV+ OPSCC.
Research Focus
Key Achievements
Top Papers
- 1
- 2